Tim Wright, Editor01.28.16
Gustavo Mahler, a 20-year biopharmaceutical industry vet, has just taken over the helm of CMC Biologics. From its small beginnings in 2001, the commercial manufacturer of therapeutic proteins now has more than 500 employees globally and operates facilities in Copenhagen, Denmark; Seattle, WA; and Berkeley, CA, from which it offers fully integrated biopharmaceutical process development and manufacturing services for clinical and commercially launched biological medicines.
Groomed over the course of a 15-year stay at Bayer in various manufacturing and general management positions in the U.S., Europe and Latin America, Mr. Mahler was heading up Bayer Healthcare’s biotechnology plant in Berkeley when he decided to join CMC Biologics in 2008, taking charge of the company’s Seattle facility. A couple years later in 2010 he took the post of chief operating and officer, which he held until taking over the chief executive role in January 2016.
Contract Pharma had the chance to talk with Mr. Mahler about his new position, plans for the company and the overall state of the market along with the trends and issues impacting it. <
Groomed over the course of a 15-year stay at Bayer in various manufacturing and general management positions in the U.S., Europe and Latin America, Mr. Mahler was heading up Bayer Healthcare’s biotechnology plant in Berkeley when he decided to join CMC Biologics in 2008, taking charge of the company’s Seattle facility. A couple years later in 2010 he took the post of chief operating and officer, which he held until taking over the chief executive role in January 2016.
Contract Pharma had the chance to talk with Mr. Mahler about his new position, plans for the company and the overall state of the market along with the trends and issues impacting it. <
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
